Compare Moderna, Inc. (MRNA) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Teucrium Wheat Fund — how do they compare? Moderna, Inc. trades at $224.38 (market cap $78.65B), while Teucrium Wheat Fund trades at $24.43 (market cap $273.67M). The key difference: Moderna, Inc. is far larger — about 287.4× Teucrium Wheat Fund's market cap, and Moderna, Inc. is trading nearer its 52-week high, Teucrium Wheat Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Teucrium Wheat Fund for 40 Days on average.
| MRNA | WEAT | |
|---|---|---|
Market Cap | $78.65B | $273.67M |
Volume | 37,373,437 | 222,576 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $203.46 | $28.00 |
52-Week Low | $22.36 | $19.88 |
Typical Hold Time | 59 Days | 40 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
WEAT trades at $24.9, down 2.31% over the past day amid a bearish technical signal from moving averages. The stock's technical indicators show neutral oscillators but selling pressure from the ADX. Recent news highlights WEAT's strong performance earlier in the year, with a 25% year-to-date gain as of July 2026, though inflation concerns persist as a market-wide theme.
The outlook for WEAT is cautious due to bearish technical momentum and macroeconomic headwinds from inflation. Investment opportunity exists if the stock holds key support levels, but risks include continued selling pressure and sensitivity to broader economic conditions. Investors should weigh technical weakness against the fund's earlier 2026 gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
